Skip to main content
Terug
Watch Compare

Xenetic Biosciences, Inc.

Datakwaliteit: 100%
XBIO
Nasdaq Manufacturing Chemicals
€ 3,15
▲ € 0,10 (3,28%)
Marktkapitalisatie: 7,22 M
Prijs
€ 3,15
Marktkapitalisatie
7,22 M
Dagbereik
€ 3,06 — € 3,15
52-Weeksbereik
€ 1,90 — € 13,93
Volume
12.464
Openen € 3,08
50D / 200D Gem.
€ 2,55
23,75% above
50D / 200D Gem.
€ 3,00
5,15% above

Quick Summary

Belangrijkste Punten

Revenue grew 26,54% annually over 5 years — strong growth
Negative free cash flow of -2,29 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,50%

Groei

Revenue Growth (5Y)
26,54%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)19,04%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-63,78%
Onder sectorgemiddelde (-53,47%)
ROIC-53,28%
Net Margin-90,07%
Op. Margin-95,23%

Veiligheid

Debt / Equity
N/A
Current Ratio4,56
Interest Coverage-19,15

Waardering

PE (TTM)
-2,69
Onder sectorgemiddelde (-1,47)
P/B Ratio1,82
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -2,7 -1,5
P/B 1,8 1,6
ROE % -63,8 -53,5
Net Margin % -90,1 -41,5
Rev Growth 5Y % 26,5 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 19,04% Revenue Growth (3Y) 8,25%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 26,54% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,98 M Net Income (TTM) -2,68 M
ROE -63,78% ROA -51,45%
Gross Margin N/A Operating Margin -95,23%
Net Margin -90,07% Free Cash Flow (TTM) -2,29 M
ROIC -53,28% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,56
Interest Coverage -19,15 Asset Turnover 0,57
Working Capital 3,96 M Tangible Book Value 3,96 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,69 Forward P/E N/A
P/B Ratio 1,82 P/S Ratio 2,42
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -31,68%
Market Cap 7,22 M Enterprise Value 7,22 M
Per Share
EPS (Diluted TTM) -1,58 Revenue / Share 1,30
FCF / Share -1,00 OCF / Share -1,00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 85,30%
SBC-Adj. FCF -2,36 M Growth Momentum -7,50

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,98 M 2,50 M 2,54 M 1,71 M 1,16 M
Net Income -2,68 M -3,96 M -4,13 M -6,55 M -5,65 M
EPS (Diluted) -1,58 -2,57 -2,71 -0,46 —
Gross Profit — — — — —
Operating Income -2,83 M -4,20 M -4,52 M -6,72 M -5,75 M
EBITDA — — — — —
R&D Expenses 3,07 M 3,29 M 3,49 M 4,77 M 3,16 M
SG&A Expenses — — — — —
D&A — — — 0,0 0,0
Interest Expense 147.997,0 249.861,0 355.757,0 167.152,0 100.467,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,36 M 6,90 M 10,61 M 14,72 M 19,82 M
Total Liabilities 968.025,0 894.263,0 809.585,0 1,07 M 1,42 M
Shareholders' Equity 7,40 M 6,01 M 9,80 M 13,65 M 18,39 M
Total Debt — — — — —
Cash & Equivalents — — — — —
Current Assets 8,05 M 6,59 M 9,59 M 13,65 M 18,72 M
Current Liabilities 968.025,0 894.263,0 809.585,0 1,07 M 1,42 M